SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Pudelko, L; Jaehrling, F; Reusch, C; Viteri, S; Stroh, C; Linde, N; Sanderson, MP; Musch, D; Lebrun, CJ; Keil, M; Esdar, C; Blaukat, A; Rosell, R; Schumacher, KM; Karachaliou, N

Karachaliou, N (corresponding author), Merck KGaA, Translat Innovat Platform Oncol, D-64293 Darmstadt, Germany.; Karachaliou, N (corresponding author), Merck KGaA, Global Clin Dev, D-64293 Darmstadt, Germany.

ISCIENCE, 2020; 23 (12):

Abstract

Tepotinib is an oralMET inhibitor approved formetastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examin......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索